Petros Pharmaceuticals, Inc. Accretion Expense
Petros Pharmaceuticals, Inc. (PTPI) reported Accretion Expense of $116.20 thousand for the 12-month period ending 2020-12-31, per its 10-K filed 2022-03-31.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AccretionExpense · last filed 2022-03-31
- Petros Pharmaceuticals, Inc. accretion expense for the quarter ending 2020-12-31 was $0.00.
- Petros Pharmaceuticals, Inc. accretion expense for the quarter ending 2020-09-30 was $32.13K.
- Petros Pharmaceuticals, Inc. accretion expense for the quarter ending 2020-06-30 was $38.67K.
- Petros Pharmaceuticals, Inc. accretion expense for the quarter ending 2020-03-31 was $45.40K.
- Petros Pharmaceuticals, Inc. accretion expense for fiscal 2020 was $116.20K.
| Period end | Accretion Expense 3 month | Accretion Expense 6 month | Accretion Expense 9 month | Accretion Expense 12 month |
|---|---|---|---|---|
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $32.13K derived: sum of 2 quarters · filed 2022-03-31 | $70.80K derived: sum of 3 quarters · filed 2022-03-31 | $116.20K 10-K · filed 2022-03-31 |
| 2020-09-30 | $32.13K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $70.80K derived: sum of 2 quarters · filed 2021-11-15 | $116.20K 10-Q · filed 2021-11-15 | |
| 2020-06-30 | $38.67K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | $84.06K 10-Q · filed 2021-08-16 | ||
| 2020-03-31 | $45.40K 10-Q · filed 2021-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B |